Clinical efficacy and safety of coseasonal initiation of Artemisia annua sublingual immunotherapy on patients with Artemisia-induced rhinoconjunctivitis.

[1]  M. Jutel,et al.  Subcutaneous birch pollen allergen immunotherapy with a depigmented polymerized extract shows only sustained and long‐term efficacy in a subgroup of monosensitized adults and adolescents with allergic rhinitis , 2022, Clinical and translational allergy.

[2]  L. Dubuske,et al.  Efficacy and safety of sublingual allergen immunotherapy. , 2022, Allergy and asthma proceedings.

[3]  Y. Shao,et al.  Clinical Efficacy and Safety of Artesimia annua-Sublingual Immunotherapy in Seasonal Allergic Rhinitis Patients Based on Different Intervention Time , 2022, International Archives of Allergy and Immunology.

[4]  H. Lou,et al.  Artemisia Annua sublingual immunotherapy for seasonal allergic rhinitis: A multicenter, randomized trial , 2020, The World Allergy Organization journal.

[5]  D. Bernstein,et al.  Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial. , 2020, The journal of allergy and clinical immunology. In practice.

[6]  H. Lou,et al.  Artemisia annua‐sublingual immunotherapy for seasonal allergic rhinitis: A randomized controlled trial , 2020, Allergy.

[7]  Jg Liu,et al.  Prevalence of pollen‐induced allergic rhinitis with high pollen exposure in grasslands of northern China , 2018, Allergy.

[8]  E. Meltzer,et al.  Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients. , 2017, The journal of allergy and clinical immunology. In practice.

[9]  T. Casale,et al.  Coseasonal Initiation of Allergen Immunotherapy: A Systematic Review. , 2016, The journal of allergy and clinical immunology. In practice.

[10]  S. Durham,et al.  Sublingual or subcutaneous immunotherapy for allergic rhinitis? , 2016, The Journal of allergy and clinical immunology.

[11]  E. Wüstenberg,et al.  Safety and Tolerability of an Intra-seasonal Initiation of the SQ-Standardised Grass Allergy Immunotherapy Tablet: A Non-interventional Observational Study Investigating the Feasibility During Routine Administration , 2013, Clinical Drug Investigation.

[12]  J. Bousquet,et al.  Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. , 2013, The Journal of allergy and clinical immunology.

[13]  A. Meadows,et al.  Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. , 2013, The Journal of allergy and clinical immunology.

[14]  G. Passalacqua,et al.  Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: A randomized controlled study , 2011, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[15]  K. Reich,et al.  Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis. , 2011, Clinical therapeutics.

[16]  R. Mösges,et al.  Sublingual immunotherapy in daily medical practice: effectiveness of different treatment schedules – IPD meta-analysis , 2010, Current medical research and opinion.

[17]  L. Klimek,et al.  Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study , 2009, Allergy.

[18]  S. La Grutta,et al.  Safety of sublingual immunotherapy started during the pollen season , 2009 .

[19]  G. Viegi,et al.  Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 * , 2008, Allergy.

[20]  E. Valovirta,et al.  Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study , 2007, Allergy.

[21]  S. Durham,et al.  Allergic rhinitis and its impact on asthma update: allergen immunotherapy. , 2007, The Journal of allergy and clinical immunology.

[22]  W. Phipatanakul.  Allergic rhinoconjunctivitis: epidemiology. , 2005, Immunology and allergy clinics of North America.

[23]  S. Burastero,et al.  Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. , 2004, The Journal of allergy and clinical immunology.

[24]  R. Merendino,et al.  Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.